Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 8:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 562 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Non-alcoholic Fatty-liver Disease Clear all
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis

NCT02933554
View directory record Official record
Conditions
Obesity, Weight Loss, Body Weight, Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease, NAFLD
Interventions
Embospheres Microspheres
Device
Lead sponsor
Keith Pereira, MD:
Other
Eligibility
22 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 15, 2026, 8:21 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

An Imaging-based Quantitative Biomarker Assay for NAFLD in Children

NCT06354491
View directory record Official record
Conditions
NAFLD, NASH
Interventions
Magnetic Resonance Imaging (MRI), Ultrasound (US)
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
10 Years to 14 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 15, 2026, 8:21 AM EDT
Completed Phase 1 Interventional

Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis

NCT01899859
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis (NASH)
Interventions
GR-MD-02, Placebo
Drug
Lead sponsor
Galectin Therapeutics Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 15, 2026, 8:21 AM EDT
Completed Phase 2 Interventional Results available

A Study of Siliphos in Adults With Non-alcoholic Steatohepatitis (NASH)

NCT00443079
View directory record Official record
Conditions
Fatty Liver
Interventions
IdB 1016 (Siliphos), Matched placebo
Drug
Lead sponsor
Heather Patton
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Oct 15, 2026, 8:21 AM EDT
Completed Not applicable Interventional Results available

Ultrasound-Based Liver Fat Quantification (LFQ) Pilot Study

NCT04657523
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
Interventions
Investigational Liver Fat Quantification Software
Device
Lead sponsor
Philips Clinical & Medical Affairs Global
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Boston, Massachusetts • Boardman, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 15, 2026, 8:21 AM EDT
Completed Phase 3 Interventional

Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Diabetes

NCT02132442
View directory record Official record
Conditions
Type 2 Diabetes, Nonalcoholic Fatty Liver Disease, Vitamin D Deficiency
Interventions
Ergocalciferol, placebo
Dietary Supplement
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
10 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Oct 15, 2026, 8:21 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)

NCT02912260
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis
Interventions
MGL-3196, Placebo
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
26
States / cities
Dothan, Alabama • Tucson, Arizona • Coronado, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 15, 2026, 8:21 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)

NCT04807868
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Standard of care liver biopsy, Fibroscan, Biospecimen Collection
Procedure · Other
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years and older
Enrollment
1,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 15, 2026, 8:21 AM EDT
Terminated Phase 4 Interventional Results available

Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)

NCT02500147
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome
Interventions
Metformin, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
13 Years to 25 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 15, 2026, 8:21 AM EDT
Completed Phase 2 Interventional Results available

A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

NCT03976401
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
EFX, Placebo
Drug
Lead sponsor
Akero Therapeutics, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
26
States / cities
Tucson, Arizona • Little Rock, Arkansas • Huntington Park, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Oct 15, 2026, 8:21 AM EDT
Terminated Not applicable Interventional Results available

Palliative Care for Non-Malignant Diseases (COMPASS Trial)

NCT03022630
View directory record Official record
Conditions
Liver Diseases, Liver Cirrhosis, NASH (Non-Alcoholic Steatohepatitis)
Interventions
Comprehensive Palliative Care services, Usual hepatic care
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 22, 2019 · Synced Oct 15, 2026, 8:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Technical Validation of MR Biomarkers of Obesity-Associated NAFLD

NCT03674528
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
Interventions
Magnetic Resonance Elastography (MRE), Liver biopsy
Other · Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
2
States / cities
La Jolla, California • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 15, 2026, 8:21 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Effect of Probiotics in Non-alcoholic Fatty Liver Disease and Steatohepatitis

NCT04175392
View directory record Official record
Conditions
Fatty Liver Disease, Fibrosis, Liver, Cirrhosis, Liver, Steatohepatitis, Nonalcoholic
Interventions
Align Probiotic Supplement Capsule, Placebos
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Farmington Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Oct 15, 2026, 8:21 AM EDT
Completed Phase 3 Interventional Results available

Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS)

NCT00063622
View directory record Official record
Conditions
Liver Diseases
Interventions
Pioglitazone, Vitamin E, Matching placebo
Drug · Dietary Supplement
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
8
States / cities
San Diego, California • San Francisco, California • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 15, 2026, 8:21 AM EDT
Terminated Not applicable Interventional Results available

The Role of Obstructive Sleep Apnea in Children With Fatty Liver Disease

NCT02134522
View directory record Official record
Conditions
Non Alcoholic Fatty Liver Disease
Interventions
Continuous positive airway pressure (CPAP).
Device
Lead sponsor
Yale University
Other
Eligibility
9 Years to 21 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 8, 2018 · Synced Oct 15, 2026, 8:21 AM EDT
Terminated Phase 2 Interventional Results available

Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)

NCT03883607
View directory record Official record
Conditions
Non Alcoholic Steatohepatitis
Interventions
Elafibranor 80mg, Elafibranor 120mg
Drug
Lead sponsor
Genfit
Industry
Eligibility
8 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
San Diego, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 15, 2026, 8:21 AM EDT
Completed Phase 2 Interventional

A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224

NCT04932512
View directory record Official record
Conditions
Steatohepatitis, Nonalcoholic
Interventions
ION224, Placebo
Drug · Other
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
50
States / cities
Chandler, Arizona • Glendale, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 15, 2026, 8:21 AM EDT
Completed Phase 1 Interventional Results available

2-Week Study In People With Nonalcoholic Fatty Liver Disease

NCT03513588
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis, Non-alcoholic Fatty Liver Disease
Interventions
Placebo, PF-06865571
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Anaheim, California • New Haven, Connecticut • South Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2020 · Synced Oct 15, 2026, 8:21 AM EDT
Active, not recruiting No phase listed Observational

Effectiveness of Endoscopic Sleeve Gastroplasty in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis

NCT05507151
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
Endoscopic Sleeve Gastroplasty
Procedure
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Timeline
2022 – 2026
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 15, 2026, 8:21 AM EDT
Terminated Phase 1 Interventional Results available

A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)

NCT06007651
View directory record Official record
Conditions
Dyslipidemias, Non-Alcoholic Fatty Liver Disease
Interventions
LY3885125, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 15, 2026, 8:21 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis

NCT03421431
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis
Interventions
EDP-305 Dose 1, EDP-305 Dose 2, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
70
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 15, 2026, 8:21 AM EDT
Recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

NCT06318169
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Interventions
Pegozafermin, Placebo
Biological · Other
Lead sponsor
89bio, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
154
States / cities
Birmingham, Alabama • Chandler, Arizona • Flagstaff, Arizona + 132 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 15, 2026, 8:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function

NCT02808312
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC)
Interventions
Cilofexor
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 15, 2026, 8:21 AM EDT
Recruiting Phase 1 Interventional

A Study of Efimosfermin Alfa in Adults With Hepatic Impairment

NCT07358546
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
Efimosfermin alfa
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Rialto, California • Tampa, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 15, 2026, 8:21 AM EDT